Document Detail


Abductor paralysis after botox injection for adductor spasmodic dysphonia.
MedLine Citation:
PMID:  20513036     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVES/HYPOTHESIS: Botulinum toxin (Botox) injections into the thyroarytenoid muscles are the current standard of care for adductor spasmodic dysphonia (ADSD). Reported adverse effects include a period of breathiness, throat pain, and difficulty with swallowing liquids. Here we report multiple cases of bilateral abductor paralysis following Botox injections for ADSD, a complication previously unreported. STUDY DESIGN: Retrospective case series. METHODS: Patients that received Botox injections for spasmodic dysphonia between January 2000 and October 2009 were evaluated. Patients with ADSD were identified. The number of treatments received and adverse effects were noted. For patients with bilateral abductor paralysis, age, sex, paralytic Botox dose, prior Botox dose, and course following paralysis were noted. RESULTS: From a database of 452 patients receiving Botox, 352 patients had been diagnosed with ADSD. Of these 352 patients, eight patients suffered bilateral abductor paralysis, and two suffered this complication twice. All affected patients were females over the age of 50 years. Most patients had received treatments prior to abductor paralysis and continued receiving after paralysis. Seven patients recovered after a brief period of activity restrictions, and one underwent a tracheotomy. The incidence of abductor paralysis after Botox injection for ADSD was 0.34%. CONCLUSIONS: Bilateral abductor paralysis is a rare complication of Botox injections for ADSD, causing difficulty with breathing upon exertion. The likely mechanism of paralysis is diffusion of Botox around the muscular process of the arytenoid to the posterior cricoarytenoid muscles. The paralysis is temporary, and watchful waiting with restriction of activity is the recommended management.
Authors:
Naren N Venkatesan; Michael M Johns; Edie R Hapner; John M DelGaudio
Related Documents :
23474806 - Perioperative treatment of patients with sepsis.
12518196 - Deletion mutations in the dystrophin gene of saudi patients with duchenne and becker mu...
23294946 - Diagnostic criteria for sepsis in burns patients.
20543416 - Brace prescription patterns in patients referred to orthopaedic clinics for adolescent ...
24998856 - Etiology and prognosis of non-convulsive status epilepticus.
23208806 - Postpartum pneumoperitoneum: an important clinical lesson.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  The Laryngoscope     Volume:  120     ISSN:  1531-4995     ISO Abbreviation:  Laryngoscope     Publication Date:  2010 Jun 
Date Detail:
Created Date:  2010-05-31     Completed Date:  2010-07-15     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8607378     Medline TA:  Laryngoscope     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1177-80     Citation Subset:  IM    
Affiliation:
Department of Otolaryngology, Emory University School of Medicine, Atlanta, Georgia, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Aged, 80 and over
Botulinum Toxin Type A / administration & dosage*,  adverse effects*
Dysphonia / drug therapy*,  physiopathology
Female
Humans
Injections, Intramuscular
Laryngeal Muscles / physiopathology*
Middle Aged
Neuromuscular Agents / administration & dosage*,  adverse effects*
Retrospective Studies
Vocal Cord Paralysis / chemically induced*,  physiopathology*
Chemical
Reg. No./Substance:
0/Botulinum Toxin Type A; 0/Neuromuscular Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Organ preservation surgery for laryngeal squamous cell carcinoma: Low incidence of thyroid cartilage...
Next Document:  Factors associated with voice therapy outcomes in the treatment of presbyphonia.